GlassScriptPhysician profile
Francis Bauer
NPI 1275609885
$6,465.60
in general payments reported to CMS, 2019-2025
36 companies · $576 in 2025
The $576 reported for 2025 was more than what 76% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,540 · 2020: $772 · 2021: $753 · 2022: $1,030 · 2023: $901 · 2024: $894 · 2025: $576.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,371.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,370.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,699.17 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $898.95 | 2019-2025 | Vraylar, Ubrelvy, Linzess |
| Pfizer INC. | $636.60 | 2019-2025 | |
| Lilly USA, LLC | $473.28 | 2019-2024 | Mounjaro, Jardiance, Zepbound |
| Amgen INC. | $347.15 | 2019-2025 | Repatha, Otezla, Repatha |
| Merck Sharp & Dohme LLC | $276.85 | 2019-2024 | Gardasil 9, Gardasil, Capvaxive |
| Glaxosmithkline, LLC. | $245.73 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Amarin Pharma, INC. | $212.52 | 2019-2022 | |
| Exact Sciences Corporation | $211.17 | 2023-2025 | Cologuard Collection Kit |
| Kowa Pharmaceuticals America, INC. | $181.55 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $172.07 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $165.67 | 2019-2025 | Airsupra, Farxiga, Lokelma |
| Axsome Therapeutics, INC. | $133.38 | 2024-2025 | Auvelity, Symbravo |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $108.47 | 2019-2024 | Xifaxan |
| Shield Therapeutics INC | $106.73 | 2022-2025 | Accrufer |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $89.45 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $72.60 | 2021-2023 | |
| Althera Pharmaceuticals LLC | $66.96 | 2021-2022 | |
| Allergan, INC. | $54.65 | 2019-2020 | |
| Eisai INC. | $40.89 | 2021-2022 | |
| Abbott Laboratories | $34.57 | 2024 | Freestyle Libre 3 |
| Sun Pharmaceutical Industries INC. | $29.35 | 2019 | |
| Gilead Sciences, INC. | $28.24 | 2019 | |
| Daiichi Sankyo INC. | $16.40 | 2023 | Injectafer |
| Horizon Therapeutics Plc | $15.92 | 2023 | Krystexxa |
| Ibsa Pharma INC. | $15.46 | 2024 | Licart, Tirosint |
| E.R. Squibb & Sons, L.L.C. | $15.22 | 2024 | Eliquis |
| Vanda Pharmaceuticals INC. | $14.19 | 2021 | |
| Arbor Pharmaceuticals, INC. | $14.16 | 2019 | |
| Sanofi Pasteur INC. | $14.14 | 2019 | |
| Avanir Pharmaceuticals, INC. | $13.91 | 2020 | |
| Otsuka America Pharmaceutical, INC. | $13.47 | 2019 | |
| Sanofi-Aventis U.S. LLC | $12.54 | 2019 | |
| Astellas Pharma US INC | $11.48 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $11.47 | 2019 | |
| Genentech USA, INC. | $11.24 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Francis Bauer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.